Hisun Pharma In-licenses China Rights to mAb Brain Cancer Candidate

Zhejiang Hisun Pharma in-licensed China rights to pritumumab, a epithelial cancer mAb being developed by Nascent Biotech of Florida. Epithelial cancers include cancers of the brain, pancreas, colon, lung and breast. Nascent  has not yet filed for US clinical trials of pritumumab, though it expects to complete a Phase I trial in the next 12 to 18 months. Hisun will have exclusive China rights to pritumumab, including manufacturing. More details.... Stock Symbols: (SHA: 600267) (OTC: NBIO) Share this with colleagues: // //